The Arora Report

Rss Facebook Twitter Linkedin

Stock Market News To Give You An Edge

Proven Track Record of Most Accurate Analysis

Stock Market News
To Give You An Edge​

Proven Track Record
of Most Accurate Analysis

COMPLETELY INDEPENDENT AND OBJECTIVE

The Arora Report, Ltd. is a rare publisher that does not accept advertisements. This way The Arora Report can not be influenced. The Arora Report also does not accept payments from any company that is the subject of the posts. The Arora Report has forsaken millions of dollars in revenues to avoid conflicts of interest. Our sole job is to help you. Read more.

COMPLETELY INDEPENDENT AND OBJECTIVE

The Arora Report, Ltd. is a rare publisher that does not accept advertisements. This way The Arora Report can not be influenced. The Arora Report also does not accept payments from any company that is the subject of the posts. The Arora Report has forsaken millions of dollars in revenues to avoid conflicts of interest. Our sole job is to help you. Read more.

WEEKLY STOCK MARKET DIGEST: WHAT PRUDENT INVESTORS NEED TO KNOW NOW

November 8, 2025

By Nigam Arora Weekly Digest from The Arora Report is popular among serious investors and money managers because they have found studying insights from the prior week gives them an edge over the coming weeks. Here is the day by day rundown from the morning capsules made available every morning before the market open in the Real Time Feeds to the paying subscribers of The Arora Report.  Please scroll down for the section ‘Protection Bands and What To Do Now.’   NASDAQ DIPS INTO CRITICAL SUPPORT ZONE, SENTIMENT SHIFTS Nov 7, 2025 To gain an edge, this is what you

Read More »

NASDAQ DIPS INTO CRITICAL SUPPORT ZONE, SENTIMENT SHIFTS

November 7, 2025

By Nigam Arora To gain an edge, this is what you need to know today. Critical Support Zone Please click here for a chart of Nasdaq 100 ETF (QQQ). Note the following: The chart shows QQQ gapped down. The chart shows that subsequently a rally brought QQQ to the bottom of the gap. The chart shows that instead of another rally to close the gap, as has often been the case in this bull market, QQQ fell. The chart shows that QQQ is now in zone 1 (support). RSI on the chart shows that even though QQQ is not oversold, it

Read More »

HUMAN LEVEL ARTIFICIAL GENERAL INTELLIGENCE ALREADY HERE, TAXING AI AGENTS, INVESTORS CELEBRATE TRUMP’S ROUGH DAY

November 6, 2025

By Nigam Arora To gain an edge, this is what you need to know today. Extreme Positive Sentiment Returns Please click here for a chart of Nasdaq 100 ETF (QQQ). Note the following: The chart shows QQQ almost touched the upper band of zone 1 (support). The chart shows that today QQQ is bouncing. It is a positive for the stock market that QQQ did not dip into the support zone. Yesterday, oral arguments in the Supreme Court case on Trump tariffs were heard.  With the justices asking tough questions of President Trump’s attorney, the likelihood of a ruling in favor

Read More »

MAKING A FORTUNE WITH THE JANUARY EFFECT — POTENTIALLY MAKE 30% GAIN IN THREE MONTHS

November 5, 2025

By Nigam Arora The January Effect The January Effect offers an opportunity to potentially make about 30% in three months. In some years, over 50% return has been generated. Of course, the annualized return can be 120 – 200%. It is a phenomenon that makes prices of certain stocks rise more in January than the market averages. History Over the last 30 years, money has been made from the January Effect about 80% of the time, broken even about 10% of the time, and lost money about 10% of the time. Why Dips Occur In Certain Stocks Providing Opportunities The practical

Read More »

MAG 7 CATCH UP TO PUSH RALLY INTO 2026, JANUARY EFFECT’S 30% UPSIDE POTENTIAL

November 4, 2025

By Nigam Arora Nigam Arora returns to the Schwab Network and weighs in on Nvidia’s (NVDA) eye-watering rally, the Mag 7’s general outperformance, and why he expects institutional investors to push the market leaders higher into the end of 2025. He sees portfolio managers buying more shares to match stock performance, pointing to pullbacks in companies like Meta Platforms (META) as one many will watch. Nigam also explains the January Effect and how investors can see upwards of 30% upside in their portfolio. November is the time to start January Effect positions. To take a free 30-day trial to paid services

Read More »

BUFFETT SELLS STOCKS – HERE IS WHAT PRUDENT INVESTORS SHOULD DO NOW, OPEC+ CHANGES STANCE

November 3, 2025

By Nigam Arora To gain an edge, this is what you need to know today. Buffett Sells Stocks Please click here for a chart of Warren Buffett’s company Berkshire Hathaway stock (BRK.B). Note the following: The Morning Capsule is about the big picture, not an individual stock.  The chart of BRK.B is being used to illustrate the point. The chart shows BRK.B stock has pulled back from highs earlier this year. The chart shows BRK.B is in zone 2 (support). RSI on the chart shows BRK.B stock is neither overbought nor oversold. Warren Buffett is the most successful investor of our

Read More »

WEEKLY STOCK MARKET DIGEST: WHAT PRUDENT INVESTORS NEED TO KNOW NOW

November 1, 2025

By Nigam Arora Weekly Digest from The Arora Report is popular among serious investors and money managers because they have found studying insights from the prior week gives them an edge over the coming weeks. Here is the day by day rundown from the morning capsules made available every morning before the market open in the Real Time Feeds to the paying subscribers of The Arora Report.  Please scroll down for the section ‘Protection Bands and What To Do Now.’   CRITICAL POWELL SPEECH AMAZON STOCK BREAKS OUT ON INSATIABLE AI DEMAND, APPLE BUOYED ON RUSH TO UPDATE IPHONES, SENTIMENT

Read More »

245% GAIN ON CANCER DETECTION COMPANY GH – ANOTHER 1000% GAIN POTENTIAL – BUYOUT TARGET

October 31, 2025

By Nigam Arora 245% Gain Guardant Health (GH) is long from $26.34.  It is trading at $91.02 as of this writing, representing a 245% gain. Buyout Target GH is a buyout target.  Cancer Screening Guardant Health is using advanced blood-based liquid biopsy tests and large clinical data sets to transform how cancer is detected, monitored, and treated. The company’s core business includes its flagship Guardant360 liquid biopsy panel, Guardant Reveal for monitoring minimal residual disease, and early blood based cancer screening test Shield.  Potential Headwinds Guardant Health is still working toward sustained profitability.  It also faces competition from other diagnostics players

Read More »

AI is power hungry. Investors will make a fortune from nuclear power for AI.
Get the list of 12 nuclear power stocks to grab your share of the profits.

AI is power hungry. Investors will make a fortune from nuclear power for AI.

Get the list of 12 nuclear power stocks to grab your share of the profits.

Big Tech is investing billions

Making A Fortune
In Nuclear Energy

Golden Age of Nuclear Energy

Skip to content